𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis

✍ Scribed by Fowler, Alpha A; Syed, Aamer A; Knowlson, Shelley; Sculthorpe, Robin; Farthing, Don; DeWilde, Christine; Farthing, Christine A; Larus, Terri L; Martin, Erika; Brophy, Donald F; Gupta, Seema; Fisher, Bernard J; Natarajan, Ramesh

Book ID
121535490
Publisher
BioMed Central
Year
2014
Tongue
English
Weight
412 KB
Volume
12
Category
Article
ISSN
1479-5876

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase I trial of dactinomycin intraven
A phase I trial of dactinomycin intravenous infusion in patients with advanced malignancies
✍ Martin S. Blumenreich; Thomas M. Woodcock; Stephen P. Richman; Mariesa K. Jones; πŸ“‚ Article πŸ“… 1985 πŸ› John Wiley and Sons 🌐 English βš– 204 KB πŸ‘ 3 views

Eighteen patients with advanced malignancies refractory to other forms of treatment were given dactinomycin (Act D) as continuous intravenous infusions. Their median age was 51 years (range, 36-67); their median performance status was 50 (range, 40-90) on the Karnofsky scale. Act D was administered

Long-term intravenous hydroxyurea infusi
Long-term intravenous hydroxyurea infusions in patients with advanced cancer. A phase I trial
✍ Martin S. Blumenreich; Michael J. Kellihan; U. Geetha Joseph; Kim A. Lalley; Eli πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 384 KB πŸ‘ 1 views

Background. Hydroxyurea is an S-phase specific drug. Constant exposure of tumor cells with a low Sphase fraction to the agent may result in improved cell kill. Because of its short half-life, a continuous intravenous infusion may result in better tumor exposure than intake by mouth. The goal of this